A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1612-1619

  Schoenfeld, Jonathan D ^a,b   Margalit, Danielle N ^b,c   Kasperzyk, Julie L ^b,d   Shui, Irene M ^d   Rider, Jennifer R ^b,d   Epstein, Mara M ^d   Meisner, Allison ^d   Kenfield, Stacey A ^d   Martin, Neil E ^b,c   Nguyen, Paul L ^b,c   Kantoff, Philip W ^b,c   Giovannucci, Edward L ^d   Stampfer, Meir J ^b,c,d   Mucci, Lorelei A ^d  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; RIBONUCLEASE L;

AGED; ALLELE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENETIC VARIABILITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RNASEL GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; C-REACTIVE PROTEIN; ENDORIBONUCLEASES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875125268     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2718     Document Type: Article

References (45)

1. National Comprehensive Cancer Network TNCC. NCCN Practice Guidelines in Oncology - Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology 2009;v.2.2009:1-46.
2. Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009;301: 2141-51.
3. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134-42.
4. Borchiellini D, Etienne-Grimaldi M-C, Thariat J, Milano G. The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treat Rev 2012;38: 737-59.
5. Parliament MB, Murray D. Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol 2010;20:232-40.
6. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008;170: 49-59.
7. Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, et al. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Radiat Oncol Biol 2007;68:1410-6.
8. Cesaretti JA, Stock RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Radiat Oncol Biol 2005;61:196-202.
9. Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, et al. Genomewide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:1292-300.
10. Al-Ahmadi W, Al-Haj L, Al-Mohanna FA, Silverman RH, Khabar KSA. RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth. Oncogene 2009;28:1782-91.
11. Castelli J, Wood KA, Youle RJ. The 2-5A system in viral infection and apoptosis. Biomed Pharmacother 1998;52:386-90.
12. Chakrabarti A, Jha BK, Silverman RH. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 2011;31:49-57.
13. Perdiguero B, Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009;29:581-98.
14. Agalliu I, Leanza SM, Smith L, Trent JM, Carpten JD, Bailey-Wilson JE, et al. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate 2010;70:1716-27.
15. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
16. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32:581-3.
17. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang W-Y, et al. RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 2007;67:849-54.
18. Fesinmeyer MD, Kwon EM, Fu R, Ostrander EA, Stanford JL. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. Prostate 2011 Feb 25. [Epub ahead of print].
19. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010;31:1597-603.
20. Mi Y-Y, Zhu L-J, Wu S, Feng N-H. An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls. Genes Nutr 2011;6: 397-402.
21. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar- Shira A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002;71:981-4.
22. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, et al. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate 2008;68:1790-7.
23. R€okman A, Ikonen T, Sepp€al€a EH, Nupponen N, Autio V, Mononen N, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70:1299-304.
24. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007;13:5959-64.
25. Wang L, Mcdonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 2002;71:116-23.
26. Wiklund F, Jonsson B-A, Brookes AJ, Str€omqvist L, Adolfsson J, Emanuelsson M, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004;10:7150-6.
27. Hatfield P, Merrick A, Harrington K, Vile R, Bateman A, Selby P, et al. Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy? Clinical Oncology 2005;17:1-11.
28. Levy A, Chargari C, Cheminant M, Simon N, Bourgier C, Deutsch E. Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol Hematol 2012 Oct 1. [Epub ahead of print].
29. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114:589-95.
30. Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979;63:1229-35.
31. Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Ménard C, Catton CN, et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 2009;15: 5576-83.
32. Hurwitz MD, Kaur P, Nagaraja GM, Bausero MA, Manola J, Asea A. Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. Radiother Oncol 2010;95:350-8.
33. Johnke RM, Edwards JM, Evans MJ, Nangami GN, Bakken NTG, Kilburn JM, et al. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. In Vivo 2009;23:827-33.
34. Lopes CO, Callera F. Three-dimensional conformal radiotherapy in prostate cancer patients: rise in interleukin 6 (IL-6) but not IL-2, IL-4, IL- 5, tumor necrosis factor-a, MIP-1-a, and LIF Levels. Int J Radiat Oncol Biol Phys 2011;82:1385-8.
35. Breyer JP, McReynolds KM, Yaspan BL, Bradley KM, Dupont WD, Smith Jr. Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes. Cancer Epidemiol Biomarkers Prev 2009;18:2137-44.
36. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006;12:5713-9.
37. Noonan-Wheeler FC, Wu W, Roehl KA, Klim A, Haugen J, Suarez BK, et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 2006; 66:49-56.
38. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA 2011;305: 2548-55.
39. Malathi K, Paranjape JM, Ganapathi R, Silverman RH. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2′,5′- oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2004;64:9144-51.
40. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 2008;105:18490-5.
41. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 2011;71:2488-96.
42. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010;28:4029-37.
43. Gao R, Price DK, Dahut WL, Reed E, Figg WD. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther 2010;10:13-8.
44. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
45. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71.